Angiodynamics Inc: Form 10-Q for the period ended Feb 29, 2012
Filed with the SEC on Apr 9, 2012 and accepted by EDGAR at Apr 9, 2012, 16:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-02-29. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-12-01 to 2012-02-29 | $51.6m | us-gaap:SalesRevenueNet |
| Revenue | 9 months2011-06-01 to 2012-02-29 | $164.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2011-12-01 to 2012-02-29 | $22.2m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2011-06-01 to 2012-02-29 | $69.3m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2011-12-01 to 2012-02-29 | $29.4m | us-gaap:GrossProfit |
| Gross profit | 9 months2011-06-01 to 2012-02-29 | $94.8m | us-gaap:GrossProfit |
| Research and development | 3 months2011-12-01 to 2012-02-29 | $4.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2011-06-01 to 2012-02-29 | $15.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2011-12-01 to 2012-02-29 | −$2.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2011-06-01 to 2012-02-29 | $3.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2011-12-01 to 2012-02-29 | $102.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2011-06-01 to 2012-02-29 | $329.0k | us-gaap:InterestExpense |
| Income tax | 3 months2011-12-01 to 2012-02-29 | −$1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2011-06-01 to 2012-02-29 | $858.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2011-12-01 to 2012-02-29 | −$1.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2011-06-01 to 2012-02-29 | $1.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2011-12-01 to 2012-02-29 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2011-06-01 to 2012-02-29 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2011-12-01 to 2012-02-29 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2011-06-01 to 2012-02-29 | $0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2011-12-01 to 2012-02-29 | 25,129,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2011-06-01 to 2012-02-29 | 25,289,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2011-06-01 to 2012-02-29 | $12.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2011-06-01 to 2012-02-29 | $1.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-02-29 | $34.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-02-29 | $211.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-02-29 | $446.6m | us-gaap:Assets |
| Current liabilities | At period end2012-02-29 | $29.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-02-29 | $35.2m | us-gaap:Liabilities |
| Long-term debt | At period end2012-02-29 | $6.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2012-02-29 | $295.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2012-02-29 | $411.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-12-155135. Last ingested by Listed: Nov 4, 2026, 20:24 ET. Listed shows no prices and gives no investment advice.